A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Competing Interest Statement

RBR is a cofounder and consultant of Alchemab Therapeutics Ltd. RC is Founder of MIROBio. JH is Director and shareholder of Nucleome Therapeutics. GS sits on GSK Vaccines SAB.

Funding Statement

The research was supported by the University of Oxford COVID-19 Research Response Fund, Wellcome Trust Core Award Grant Number 203141/Z/16/Z and the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

South Central Oxford C Research Ethics Committee (REC) in England (Sepsis Immunomics REC reference 19/SC/0296; ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections REC reference 13/SC/0149)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes